Anteris Technologies (AVR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 May, 2026Executive summary
A special meeting of stockholders is scheduled for September 4, 2025, to be held virtually, with voting available online, by phone, or by mail prior to the meeting.
Only stockholders of record as of August 11, 2025, are entitled to vote; CHESS Depositary Interest (CDI) holders may attend as guests and instruct their nominee to vote on their behalf.
The meeting will address two main proposals: approval of an ASX waiver to allow issuance of new securities beyond the 15% limit without stockholder approval, and approval to adjourn the meeting if more votes are needed.
The board unanimously recommends voting in favor of both proposals.
Voting matters and shareholder proposals
Proposal One seeks approval for an ASX waiver from Listing Rule 7.1, enabling the company to issue new securities in excess of 15% of outstanding shares without prior stockholder approval for three years.
Proposal Two requests authority to adjourn the meeting if necessary to solicit additional proxies for Proposal One.
Both proposals are non-routine matters; brokers cannot vote uninstructed shares on these items.
The board recommends a "FOR" vote on both proposals.
Shareholder proposals for the 2025 annual meeting must comply with SEC and bylaw requirements and be submitted within specified timeframes.
Board of directors and corporate governance
The board is responsible for soliciting proxies and making recommendations on voting matters.
A list of stockholders entitled to vote will be available for inspection prior to and during the meeting.
Latest events from Anteris Technologies
- Q2 2026 featured global trial expansion, U.S. Medicare reimbursement, and strong cash growth.AVR
Q2 2026 TU - Shareholders considered and voted on a US redomicile scheme, with board and expert support.AVR
Share Scheme Meeting - Pre-commercial heart device company targets U.S. IPO to fund pivotal trials amid high growth potential and risk.AVR
Registration filing - Raising $90.6M to fund heart valve trials, but faces ongoing losses and high risk.AVR
Registration filing - 2024 net loss rose to $76M, cash insufficient for 12 months, additional funding required.AVR
H2 2024 - US IPO, clinical milestones, and strong R&D focus marked a pivotal year.AVR
AGM 2025 - Operating losses widened as PARADIGM Trial preparations accelerated and cash fell to $28.4M.AVR
Q2 2025 TU - Option holders voted on a scheme to exchange their options for equivalent securities in ATGC.AVR
Option Scheme Meeting - Net loss rose 36% to $21.9M as R&D and trial costs surged, straining cash reserves.AVR
Q1 2025